1. Home
  2. PRCT vs PHVS Comparison

PRCT vs PHVS Comparison

Compare PRCT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROCEPT BioRobotics Corporation

PRCT

PROCEPT BioRobotics Corporation

HOLD

Current Price

$25.22

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$28.86

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRCT
PHVS
Founded
2009
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.8B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PRCT
PHVS
Price
$25.22
$28.86
Analyst Decision
Buy
Buy
Analyst Count
11
11
Target Price
$35.44
$41.82
AVG Volume (30 Days)
1.1M
202.7K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
1.71
N/A
EPS
N/A
N/A
Revenue
$308,054,000.00
N/A
Revenue This Year
$31.34
N/A
Revenue Next Year
$24.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
37.22
N/A
52 Week Low
$19.35
$13.81
52 Week High
$64.89
$29.85

Technical Indicators

Market Signals
Indicator
PRCT
PHVS
Relative Strength Index (RSI) 50.21 58.00
Support Level $22.81 $24.55
Resistance Level $28.57 $29.82
Average True Range (ATR) 1.24 1.33
MACD 0.18 0.13
Stochastic Oscillator 65.64 71.47

Price Performance

Historical Comparison
PRCT
PHVS

About PRCT PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: